Skip to content
Screener

LivaNova LIVN Total Liabilities & Equity

Total Liabilities & Equity at other companies

Abbott logo
AbbottABT
$109.22B+30.0%
Haemonetics logo
HaemoneticsHAE
$2.37B-3.9%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$98.9M-10.3%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
$911.38M+24.7%
Medtronic logo
MedtronicMDT
$93.03B+1.5%
ITG
Integer HoldingsITGR
$3.41B+3.5%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemJune 30, 2026December 31, 2025
Shareholders’ Equity:
Ordinary Shares, £1.00 par value: Unlimited shares authorized; 55,601,145 shares issued and 55,051,768 shares outstanding as of June 30, 2026; 55,535,181 shares issued and 54,649,085 shares outstanding as of December 31, 202584,59984,564
Additional paid-in capital2,270,6992,254,980
Accumulated other comprehensive (loss) income(14,386)7,330
Accumulated deficit(1,014,858)(1,145,721)
Treasury shares at cost, 549,377 ordinary shares as of June 30, 2026; 886,096 ordinary shares as of December 31, 2025(732)(1,166)
Total Shareholders’ Equity1,325,3221,199,987
Total Liabilities and Shareholders’ Equity$2,640,861$2,606,053

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's total liabilities & equity?
LivaNova (LIVN) reported total liabilities & equity of $2.64B in Q2 2026.
How has LivaNova's total liabilities & equity changed year-over-year?
LivaNova's total liabilities & equity increased by 5.4% year-over-year, from $2.51B to $2.64B.
What is the long-term trend for LivaNova's total liabilities & equity?
Over 5 years (2020 to 2025), LivaNova's total liabilities & equity has grown at a 1.7% compound annual growth rate (CAGR), from $2.4B to $2.61B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about LivaNova's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude